We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Enteris And Sanofi Combine To Treat Diabetes

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Enteris And Sanofi Combine To Treat Diabetes"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Enteris BioPharma, Inc., has announced the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides.

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “Our agreement with Sanofi is further validation of the tremendous value our Peptelligence platform program offers in the therapeutic peptide field. We are excited to work with an industry leader like Sanofi.”

This article has been republished from materials provided by Enteris. Note: material may have been edited for length and content. For further information, please contact the cited source.